Trial of potential Ebola treatments begins in DR Congo: WHO
· Medical Xpressedited by Andrew Zinin
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process
Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
reputable news agency
proofread
The GIST Add as preferred source
The trial of two potential treatments for the Bundibugyo species of Ebola behind the deadly outbreak in the DR Congo began in the country Thursday, the World Health Organization said.
There are no approved vaccines or treatments for the rare strain, which has been spreading in the northeastern provinces of the Democratic Republic of Congo.
There have been 1,406 confirmed cases and 438 confirmed deaths in the DRC, while 208 people have recovered from the virus, according to figures from the WHO.
"Today, the clinical trial of two therapeutics began, with the enrollment of the first patient," with the trial evaluating the monoclonal antibody MBP134 and the antiviral drug remdesivir, alone and in combination, WHO chief Tedros Adhanom Ghebreyesus told reporters.
He said the study was being conducted by the DRC's National Institute for Biomedical Research, backed by partners including the WHO.
"Patients who enroll in the trial will receive comprehensive supportive care and close follow-up," Tedros said.
"We are also working to ensure they have access to the two drugs should they prove safe and efficacious in the trial."
Key medical concepts
Clinical categories
Infectious diseasesClinical pharmacology Who's behind this story?
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 AFP
Citation: Trial of potential Ebola treatments begins in DR Congo: WHO (2026, July 2) retrieved 2 July 2026 from https://medicalxpress.com/news/2026-07-trial-potential-ebola-treatments-dr.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.